EG382639 Inhibitors
EG382639 inhibitors are a class of small molecules specifically designed to inhibit the activity of the enzyme EG382639, a target known for its regulatory role in certain biological pathways. These inhibitors typically possess a core scaffold that enables them to bind selectively to the active site of EG382639, preventing its normal substrate interactions and subsequent downstream signaling. The structure-activity relationship (SAR) of these compounds is critical, with modifications to the core scaffold influencing binding affinity, selectivity, and inhibitory potential. Commonly, they contain heterocyclic structures or aromatic rings that enhance hydrophobic interactions within the enzyme's binding pocket. Additionally, side chains or substituents are often optimized to interact with specific amino acid residues within the active site, improving binding specificity and potency. EG382639 inhibitors are designed to have high selectivity for their target to minimize off-target effects and reduce interference with other cellular proteins or pathways.
These inhibitors are also characterized by their physicochemical properties, which are tuned for optimal enzyme binding and bioavailability. Key properties include lipophilicity, which affects cellular permeability, and hydrogen bonding capacity, which can influence binding affinity and solubility. Modifications to these inhibitors often focus on optimizing these parameters to enhance their inhibitory efficiency while maintaining desirable pharmacokinetic characteristics. Additionally, researchers evaluate the stability of these compounds under physiological conditions to ensure they retain their functional integrity when used in biological systems. Structural variations among EG382639 inhibitors allow for the fine-tuning of their interactions with EG382639, aiming for increased binding efficiency and specificity. The molecular design of these inhibitors often involves balancing features like size, flexibility, and electronic characteristics to achieve a robust and selective inhibition of the enzyme's activity, making them valuable tools for studying EG382639's role in various biochemical processes.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
DNA transcription inhibitor binding to RNA polymerase. Actinomycin D directly inhibits Zbtb42 by preventing RNA polymerase II-mediated transcription, disrupting its ability to bind specific DNA sequences within cis-regulatory regions. | ||||||
α-Amanitin | 23109-05-9 | sc-202440 sc-202440A | 1 mg 5 mg | $269.00 $1050.00 | 26 | |
RNA polymerase II inhibitor affecting transcription. Alpha-Amanitin directly inhibits Zbtb42 by targeting RNA polymerase II, leading to a specific block in RNA synthesis and negatively impacting DNA-binding transcription factor activity. | ||||||
Triptolide | 38748-32-2 | sc-200122 sc-200122A | 1 mg 5 mg | $90.00 $204.00 | 13 | |
Inhibitor of transcriptional elongation. Triptolide directly inhibits Zbtb42 by suppressing RNA polymerase II elongation, disrupting its ability to bind cis-regulatory regions and exerting negative regulation on transcription by RNA polymerase II. | ||||||
CX-5461 | 1138549-36-6 | sc-507275 | 5 mg | $245.00 | ||
Selective RNA polymerase I inhibitor. CX-5461 indirectly inhibits Zbtb42 by disrupting ribosomal RNA synthesis, potentially impacting RNA polymerase II-specific DNA binding and leading to negative regulation of transcription within cis-regulatory regions. | ||||||
Flavopiridol | 146426-40-6 | sc-202157 sc-202157A | 5 mg 25 mg | $78.00 $259.00 | 41 | |
CDK inhibitor affecting transcription. Flavopiridol directly inhibits Zbtb42 by targeting CDKs, crucial for RNA polymerase II activity, potentially affecting its DNA-binding transcription factor function and negative regulation of transcription. | ||||||
DRB | 53-85-0 | sc-200581 sc-200581A sc-200581B sc-200581C | 10 mg 50 mg 100 mg 250 mg | $43.00 $189.00 $316.00 $663.00 | 6 | |
Inhibitor of transcription elongation. DRB directly inhibits Zbtb42 by impeding RNA polymerase II elongation, hindering its interaction with cis-regulatory regions and leading to negative regulation of transcription by RNA polymerase II. | ||||||
C646 | 328968-36-1 | sc-364452 sc-364452A | 10 mg 50 mg | $265.00 $944.00 | 5 | |
p300/CBP inhibitor affecting transcription. C646 directly inhibits Zbtb42 by targeting p300/CBP, modulating its coactivator function in RNA polymerase II-mediated transcription and potentially disrupting DNA-binding transcription factor activity. | ||||||
Fludarabine | 21679-14-1 | sc-204755 sc-204755A | 5 mg 25 mg | $58.00 $204.00 | 15 | |
Nucleoside analog inhibiting RNA polymerase II. Fludarabine directly inhibits Zbtb42 by incorporating into RNA, disrupting RNA polymerase II activity, and negatively impacting DNA-binding transcription factor function within cis-regulatory regions. | ||||||
Etoposide (VP-16) | 33419-42-0 | sc-3512B sc-3512 sc-3512A | 10 mg 100 mg 500 mg | $51.00 $231.00 $523.00 | 63 | |
Topoisomerase II inhibitor affecting DNA structure. Etoposide directly inhibits Zbtb42 by inducing DNA damage and altering chromatin structure, potentially disrupting its DNA-binding transcription factor activity within cis-regulatory regions. | ||||||